Vasomune lands up to $197K from Canada's NRC IRAP for vascular leak therapy
What's the deal? Vasomune TherapeuticsDealroom has a profile for this one. Try Dealroom → has received a grant of up to US$205.6K through the National Research Council of Canada Industrial Research Assistance Program (NRC IRAP)Dealroom has a profile for this one. Try Dealroom →. The Toronto-based clinical-stage biopharmaceutical company will use the funding to advance Pegevongitide (AV-001), its lead therapy targeting vascular leak.
What's the endgame? VasomuneDealroom has a profile for this one. Try Dealroom → is developing medicines to counter endotheliopathy — the breakdown of the barrier lining blood vessels, which lets fluid and proteins escape into surrounding tissues and can cause edema and organ failure. Pegevongitide is a first-in-class Tie2 receptor agonist designed to stabilise the vascular endothelium and block that leak.
What's the money for? The grant will support development of a subcutaneous formulation of the drug, expanding delivery beyond intravenous administration. That could enable earlier intervention across both civilian and military settings.
Vascular leak underlies conditions of concern to defence and public health authorities, including acute respiratory distress syndrome (ARDS), hemorrhagic shock, trauma, and shock following severe burns.
Why now? NRC IRAPDealroom has a profile for this one. Try Dealroom → previously backed Vasomune's Phase 1 development program. "Vascular leak is a common theme that links many combat-relevant injuries and critical illnesses, and this support will help us advance a therapeutic that treats vascular leak directly, regardless of the underlying cause," said chief executive officer Brian Jahns.
Pegevongitide was discovered at Sunnybrook Research InstituteDealroom has a profile for this one. Try Dealroom → in Toronto and is being developed under a co-development agreement with Japan's AnGes.
The signal: At roughly $197,000, this is a modest, non-dilutive top-up rather than a major capital raise — it sits near the middle of comparable deals by size. But it extends a government agency's repeat backing of a dual-use biotech, signalling continued public-sector interest in therapies that bridge civilian critical care and military medicine.
Read more: business.thepilotnews.com
Image credit: foteih
